The Benefit of Liso-Cel Therapy Across Lymphoma Subgroups

CU Cancer Center member Manali Kamdar, MD, discusses the promising results of liso-cel (Breyanzi), a CD19-directed CAR T-cell therapy, in treating relapsed/refractory mantle cell lymphoma (MCL) and other lymphoma subgroups. Kamdar emphasizes the potential benefits of using liso-cel in earlier lines of treatment, particularly in high-risk patients with better-preserved T-cell health, to improve response rates and durability of remission while managing associated toxicities.